Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
Background Distribution of COVID-19 vaccines has been surrounded by suspicions and rumors making it necessary to provide the public with accurate reports from trustworthy experts such as healthcare professionals. Methods We distributed a questionnaire in Jordan among physicians, dentists and nurses who received a COVID-19 vaccine to explore the side effects (SE) they encountered after the first or the second dose of one of three vaccines namely: AstraZeneca Vaxzevria (AZ), Pfizer-BioNTeck (PB), and SinoPharm (SP) vaccines. Results A total of 409 professionals participated. Approximately 18% and 31% of participants reported no SE after the first dose and second dose, respectively. The remainder had mostly local side effects related to injection site (74%). Systemic side effects in the form of fatigue (52%), myalgia (44%), headache (42%), and fever (35%) prevailed mainly after the first dose. These were significantly associated with AZ vaccine, and age ≤ 45 years (p = 0.000 and 0.01, respectively). No serious SE were reported. Conclusions We can conclude that SE of COVID-19 vaccines distributed in Jordan are within the common range known so far for these vaccines. Further studies are needed to include larger sample size and longer follow-up period to monitor possible serious and long-term SE of the vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Vaccines - 9(2021), 6 vom: 01. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abu-Hammad, Osama [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AstraZeneca vaccine |
|---|
| Anmerkungen: |
Date Revised 14.07.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines9060577 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327526343 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327526343 | ||
| 003 | DE-627 | ||
| 005 | 20231225200958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines9060577 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327526343 | ||
| 035 | |a (NLM)34205917 | ||
| 035 | |a (PII)577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abu-Hammad, Osama |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.07.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background Distribution of COVID-19 vaccines has been surrounded by suspicions and rumors making it necessary to provide the public with accurate reports from trustworthy experts such as healthcare professionals. Methods We distributed a questionnaire in Jordan among physicians, dentists and nurses who received a COVID-19 vaccine to explore the side effects (SE) they encountered after the first or the second dose of one of three vaccines namely: AstraZeneca Vaxzevria (AZ), Pfizer-BioNTeck (PB), and SinoPharm (SP) vaccines. Results A total of 409 professionals participated. Approximately 18% and 31% of participants reported no SE after the first dose and second dose, respectively. The remainder had mostly local side effects related to injection site (74%). Systemic side effects in the form of fatigue (52%), myalgia (44%), headache (42%), and fever (35%) prevailed mainly after the first dose. These were significantly associated with AZ vaccine, and age ≤ 45 years (p = 0.000 and 0.01, respectively). No serious SE were reported. Conclusions We can conclude that SE of COVID-19 vaccines distributed in Jordan are within the common range known so far for these vaccines. Further studies are needed to include larger sample size and longer follow-up period to monitor possible serious and long-term SE of the vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AstraZeneca vaccine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Pfizer-Bionteck vaccine | |
| 650 | 4 | |a SinoPharm | |
| 650 | 4 | |a dentists | |
| 650 | 4 | |a healthcare professionals | |
| 650 | 4 | |a nurses | |
| 650 | 4 | |a physicians | |
| 650 | 4 | |a side effects | |
| 700 | 1 | |a Alduraidi, Hamza |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Hammad, Shaden |e verfasserin |4 aut | |
| 700 | 1 | |a Alnazzawi, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Babkair, Hamzah |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Hammad, Abdalla |e verfasserin |4 aut | |
| 700 | 1 | |a Nourwali, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Qasem, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Dar-Odeh, Najla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 9(2021), 6 vom: 01. Juni |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:6 |g day:01 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines9060577 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 6 |b 01 |c 06 | ||